{"id":11077,"date":"2024-10-09T10:34:26","date_gmt":"2024-10-09T07:34:26","guid":{"rendered":"https:\/\/ozgurkilickesmez.com\/?p=11077"},"modified":"2026-10-13T22:22:14","modified_gmt":"2026-10-13T19:22:14","slug":"bethesda-classification","status":"publish","type":"post","link":"https:\/\/ozgurkilickesmez.com\/en\/bethesda-classification\/","title":{"rendered":"Bethesda Classification for Thyroid Cytology: Categories and Cancer Risk"},"content":{"rendered":"

The Bethesda classification is a standardized reporting system for thyroid cytology obtained through fine-needle aspiration biopsy. It categorizes thyroid nodules into six diagnostic groups, guiding clinical decisions and ensuring consistency in pathology reporting.<\/span><\/p>\n

Each Bethesda category provides an estimated risk of malignancy, ranging from non-diagnostic to malignant. This helps clinicians determine whether follow-up, repeat biopsy, molecular testing, or surgical intervention is required.<\/span><\/p>\n

The classification system improves communication between cytopathologists and treating physicians. By reducing ambiguity in reports, it enhances diagnostic accuracy and ensures appropriate patient management strategies.<\/span><\/p>\n

Bethesda classification is globally recognized in thyroid cancer diagnostics. Its use minimizes unnecessary surgeries while enabling timely treatment of malignant or suspicious thyroid nodules.<\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Classification Name<\/td>\nBethesda Classification<\/td>\n<\/tr>\n
Definition<\/td>\nA standard classification system used to report the results of thyroid fine needle aspiration biopsies (FNAB) and to determine cancer risk.<\/td>\n<\/tr>\n
Fields of Use<\/td>\nPathological evaluation of thyroid nodules, cancer risk analysis, and determining treatment and follow-up decisions.<\/td>\n<\/tr>\n
Classification Categories<\/td>\nThe Bethesda Classification consists of six categories, each classified according to cancer risk.<\/td>\n<\/tr>\n
Categories and Descriptions<\/td>\n1. Insufficient\/Non-diagnostic: Sample lacking adequate cells (cancer risk 1-4%);
\nBenign: Benign (cancer risk 0-3%);Atypia of Undetermined Significance (AUS)\/Follicular Lesion: Uncertain (cancer risk 5-15%);<\/p>\n

Follicular Neoplasm or Suspicious for Follicular Neoplasm: Suspected follicular tumor (cancer risk 15-30%);<\/p>\n

Suspicious for Malignancy: Suspicion of cancer (cancer risk 60-75%);<\/p>\n

Malignant: Cancer diagnosis (97-99%).<\/td>\n<\/tr>\n

Treatment Methods<\/td>\nDepending on the result, observation, repeat biopsy, surgical intervention, or radioactive iodine<\/a> therapy is planned; in low-risk categories, observation is generally recommended, while surgical treatment is preferred in high-risk categories.<\/td>\n<\/tr>\n
Advantages<\/td>\nProvides diagnostic standardization, determines cancer risk, prevents unnecessary surgical interventions, and guides treatment planning.<\/td>\n<\/tr>\n
Follow-up and Monitoring<\/td>\nCancer risk is assessed according to category; annual monitoring can be performed for benign lesions, while post-surgical follow-up is important for high-risk lesions.<\/td>\n<\/tr>\n
Clinical Relevance<\/td>\nReliably determines thyroid cancer risk, provides standardization in patient management by distinguishing between low- and high-risk nodules.<\/td>\n<\/tr>\n
Associated Diseases<\/td>\nThyroid nodules, thyroid cancer (papillary, follicular, medullary), thyroiditis (such as Hashimoto), hyperplasia, and other thyroid diseases.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\t

\n\t\t
\n\t\t\t\t\t\t\t\t\t\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\n\n\t\t
\n\t\t\t\n\n
\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n
\n\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\"Interventional\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n